These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7059416)

  • 1. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
    McInnes GT; Shelton JR; Harrison IR; Perkins RM; Palmer RF
    Br J Clin Pharmacol; 1982 Feb; 13(2):187-94. PubMed ID: 7059416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
    McInnes GT; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
    McInnes GT; Harrison IR; Shelton JR; Perkins RM; Clarke JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):169-74. PubMed ID: 6487456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L; Harrison I; Shelton J; Tidd M
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationships for spironolactone at steady state.
    McInnes GT; Perkins RM; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1982 Mar; 31(3):317-23. PubMed ID: 7060315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D; Ramsay L; Auty R; Branch R; Tidd M
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE; Shelton JR; Tidd MJ
    Br J Clin Pharmacol; 1976 Jun; 3(3):475-82. PubMed ID: 788750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone dose-response relationships in healthy subjects.
    McInnes GT; Perkins RM; Shelton JR; Harrison IR
    Br J Clin Pharmacol; 1982 Apr; 13(4):513-8. PubMed ID: 7066166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.
    McInnes GT; Harrison IR; Shelton JR; Perkins RM
    Br J Clin Pharmacol; 1981 Nov; 12(5):743-7. PubMed ID: 7332740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M; Fordtran JS; Emmett M
    Am J Kidney Dis; 1998 Jul; 32(1):47-51. PubMed ID: 9669423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic.
    McInnes GT; Clarke JM; Shelton JR
    Clin Pharmacol Ther; 1983 Jan; 33(1):35-43. PubMed ID: 6848297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.
    Wenzl HH; Fine KD; Santa Ana CA; Porter JL; Fordtran JS
    Dig Dis Sci; 1997 Jan; 42(1):119-28. PubMed ID: 9009126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative potency of amiloride and spironolactone in healthy man.
    McInnes GT
    Clin Pharmacol Ther; 1982 Apr; 31(4):472-7. PubMed ID: 7060327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.
    McInnes GT; Shelton JR; Ramsay LE; Harrison IR; Asbury MJ; Clarke JM; Perkins RM; Venning GR
    Br J Clin Pharmacol; 1982 Mar; 13(3):331-9. PubMed ID: 6460516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on spirolactone steroid antagonists in ACTH-induced hypertension in sheep.
    Reid AF; Coghlan JP; Spence CD; Whitworth JA; Scoggins BA
    J Steroid Biochem; 1989 Dec; 33(6):1213-21. PubMed ID: 2559253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.